The Week in Review: Deals, Earnings and a Profile of LEAD Therapeutics, Inc.

Published: Sep 04, 2008

September 4, 2008 -- China Biologic Products gained control of a competitor in the plasma-based pharmaceutical sector; Three Rivers Pharma obtained the right to sell Infergen in China; WuXi PharmaTech and Covance will not go ahead with their previously announced joint ownership of a preclinical laboratory; we profiled LEAD Therapeutics, a company that wants “to make drug discovery fundable"; Genesis Pharmaceuticals had a very positive fiscal 2008 with a 31% increase in revenues; Shengtai Pharma reported that its 2008 revenues climbed 76%; and Tianyin Pharma also released very positive results. More details... Stock Symbols: (OTCBB: CBPO) (NYSE: WX) (NYSE: CVD) (OTCBB: GNPH) (OTCBB: SGTI) (AMEX:TPI)

Back to news